Chamber and committees

I refer the member to the answer to question S6W-14615 on 6 March 2023. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at: https://www.parliament.scot/chamber-and-committees/questions-and-answers .

The Learning Estate Investment Programme’s (LEIP) outcomes-based funding model was designed by Scottish Government, Local Government and Scottish Futures Trust (SFT). The funding model was established to support the implementation of the Learning Estate Strategy which was produced was produced collaboratively by Scottish Government and Local Government. The concepts, principles and outcomes for the LEIP, as well as the mechanics of the funding model, were agreed in workshops between Scottish Government, Local Government and SFT, under the governance of an investment programme board which was co-chaired by Scottish Government and COSLA.

The use of the LEIP funding model and the associated outcomes have been ratified by COSLA Leaders, and further information on the mechanics of the model are published and available on SFT’s website.

The LEIP board, which meets quarterly, is co-chaired by Scottish Government and COSLA. The board has membership and representation from Scottish Government, COSLA, SOLACE, Local Authority networks and SFT. This governance structure provides oversight and direction to the LEIP - including on the outcomes to be measured, the assessment process for projects and the funding model - as the programme has developed.

We continue to engage with local authorities on an ongoing basis, including workshops on the funding model for each phase of the LEIP, and dedicated workshops with local authorities for each project.

The PVG Scheme was established on 28 February 2011. The number of PVG disclosures completed in each financial year since that date is set out in the following table.

Disclosure Scotland’s Annual Report and Accounts, which includes figures about PVG disclosures, is laid in the Parliament each year and published on the MyGov.Scot website: Disclosure Scotland Annual Report and Accounts 2021-22

Any business with questions or concerns about registration should contact Circularity Scotland (CSL) for advice and guidance. They can do this via their website or their dedicated helpline.

CSL has ongoing communications with businesses to raise awareness and help them understand their obligations as part of the Deposit Return Scheme (DRS) and what they need to do to comply. This includes a recent series of information workshops across the country for businesses affected by DRS.

I also meet regularly with industry stakeholders to discuss their concerns and to help them prepare for the scheme’s launch in August.

The Scottish Government does not hold this information.

The release of non-native common pheasant and red-legged partridge for shooting purposes is permitted under Section 14 (2A) of the Wildlife and Countryside Act 1981. There is no statutory requirement under this legislation (or any other) requiring those releasing non-native gamebirds to submit records of numbers of birds released.

In April 2021, Scottish Government commissioned Public Health Scotland to develop and deliver the Scottish Cardiac Audit Programme. To date, hypertension and atrial fibrillation have been included as part of draft indicators shared in autumn 2022.

We continue to work with PHS to develop this programme.

I refer the member to the answer to question S6W-14639 on 7 March 2023. All answers to written Parliamentary Questions are available on the Parliament's website, the search facility for which can be found at https://www.parliament.scot/chamber-and-committees/written-questions-and-answers

In Scotland, wildfowling on the foreshore is a public right. While the Parliament could potentially legislate on wildfowling, the Scottish Government does not have any current plans to bring forward legislation to prevent wildfowling on the foreshore.

The following table details the precision medicines accepted by the Scottish Medicines Consortium where the companion diagnostic test is not yet offered by NHS Scotland laboratories, and the anticipated roll-out of the appropriate test.

Validation is required for every companion diagnostic test to ensure the accuracy of the test meets the indication required. A number of tests have completed validation and are currently awaiting implementation throughout the course of 2023. We continue to work with key partners, such as the Scottish Strategic Network for Genomics Medicine (SSNGM), to ensure there is capacity within laboratories for companion diagnostics tests.

*Olaparib (SMC2366) for the treatment of prostate cancer

**Olaparib (SMC2368) for the treatment of ovarian, fallopian tube or primary peritoneal cancer requires two companion diagnostics tests in order for patients to access the treatment. One of the tests, BRCA, is available in NHS Scotland labs, however, the other, HRD, is not available due to its complexity. While testing isn’t available in NHS laboratories, it is available through an alternative provider ensuring patients can still access the medicine.

The delivery of Scotland Genomics strategy is being overseen by the Scottish Strategic Network for Genomic Medicine (SSNGM). The Network is supported by a Scottish Government funded transformation team which is led by a Consultant Clinical Scientist and supported by Clinical Leads for rare disease and cancer.

The Network draws on a wide pool of stakeholders including clinicians and scientists. Many of which are supporting us directly to shape The Strategy through various working groups.